Electra Therapeutics (ETRA) news
Recent news
Electra Therapeutics - Q3 2026 net loss totals $23.90 mln
Electra Therapeutics Inc. (ETRA) reported net loss of $23.90 million , according to its latest financial results. The company, which operates in the biological products sector under SIC code 2836, continues to focus on advancing its therapeutic pipeline while managing operational costs. The Q3 loss…
AInvest Wire · 7d agoBio-pharmaceutical stocks rose in premarket trading, with CPHI up 6.55%, ETRA gaining 2.92% and REGN rising 1.90%.
AInvest Wire · Nov 10, 2026Electra Therapeutics, Inc.: JP Morgan initiates coverage with overweight rating; price target $36
JP Morgan has initiated coverage on Electra Therapeutics, Inc. (ETRA) with an "overweight" rating and a 12-month price target of $36 per share. This recommendation aligns with the broader analyst consensus, which currently rates ETRA as a "Strong Buy" based on insights from three analysts. The…
AInvest Wire · Oct 22, 2026Bio-pharmaceutical stocks rose in premarket trading, with LQDA up 36.5%, ETRA gaining 7.4% and DGX rising 4.7%.
Bio-pharmaceutical stocks saw gains in premarket trading on October 14, 2026, with several key names posting significant price increases. Liquidia Technologies (LQDA) led the sector with a 36.5% rise, driven by optimism surrounding its YUTREPIA launch and recent developments in its pipeline .…
AInvest Wire · Oct 14, 2026Electra Therapeutics, Inc.: Jefferies initiates coverage with buy rating; price target $32
AInvest Wire · Oct 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

